292 related articles for article (PubMed ID: 36525231)
1. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer.
Rodríguez Pérez A; Felip Font E; Chicas-Sett R; Montero-Luis Á; de Paz Arias L; González-Del-Alba A; López-Campos F; López López C; Hernando Requejo O; Conde-Moreno AJ; Arranz Arija JÁ; de Castro Carpeño J
Clin Transl Oncol; 2023 Apr; 25(4):882-896. PubMed ID: 36525231
[TBL] [Abstract][Full Text] [Related]
2. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer.
Conde-Moreno AJ; González-Del-Alba A; López-Campos F; López López C; Requejo OH; de Castro Carpeño J; Chicas-Sett R; de Paz Arias L; Montero-Luis Á; Pérez AR; Font EF; Arija JÁA
Clin Transl Oncol; 2023 Apr; 25(4):897-911. PubMed ID: 36525230
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Iyengar P; All S; Berry MF; Boike TP; Bradfield L; Dingemans AC; Feldman J; Gomez DR; Hesketh PJ; Jabbour SK; Jeter M; Josipovic M; Lievens Y; McDonald F; Perez BA; Ricardi U; Ruffini E; De Ruysscher D; Saeed H; Schneider BJ; Senan S; Widder J; Guckenberger M
Pract Radiat Oncol; 2023; 13(5):393-412. PubMed ID: 37294262
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy for metastatic lung metastases.
Kimura T; Fujiwara T; Kameoka T; Adachi Y; Kariya S
Jpn J Radiol; 2022 Oct; 40(10):995-1005. PubMed ID: 36097233
[TBL] [Abstract][Full Text] [Related]
5. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
6. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
[TBL] [Abstract][Full Text] [Related]
7. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
Kent CL; McDuff SGR; Salama JK
Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases.
Verma V; Yegya-Raman N; Sprave T; Han G; Kantarjian HM; Welsh JW; Chang JY; Lin SH
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):977-988. PubMed ID: 35675852
[TBL] [Abstract][Full Text] [Related]
12. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of oligometastatic or oligoprogression cancer].
Bourgier C; Latorzeff I; Fenoglietto P; Boisselier P; Charissoux M; Llacer C; Lemanski C; Riou O; Farcy-Jacquet MP; Azria D
Cancer Radiother; 2019 Oct; 23(6-7):482-485. PubMed ID: 31495737
[TBL] [Abstract][Full Text] [Related]
14. Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective.
Piroth MD; Krug D; Feyer P; Baumann R; Combs S; Duma MN; Dunst J; Fastner G; Fietkau R; Guckenberger M; Haase W; Harms W; Hehr T; Sedlmayer F; Souchon R; Strnad V; Budach W
Strahlenther Onkol; 2022 Jul; 198(7):601-611. PubMed ID: 35527272
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.
Schneider BJ; Daly ME; Kennedy EB; Antonoff MB; Broderick S; Feldman J; Jolly S; Meyers B; Rocco G; Rusthoven C; Slotman BJ; Sterman DH; Stiles BM
J Clin Oncol; 2018 Mar; 36(7):710-719. PubMed ID: 29106810
[TBL] [Abstract][Full Text] [Related]
16. American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.
Amini A; Verma V; Simone CB; Chetty IJ; Chun SG; Donington J; Edelman MJ; Higgins KA; Kestin LL; Movsas B; Rodrigues GB; Rosenzweig KE; Rybkin II; Slotman BJ; Wolf A; Chang JY
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):361-375. PubMed ID: 34571054
[TBL] [Abstract][Full Text] [Related]
17. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
18. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
19. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
Lievens Y; Guckenberger M; Gomez D; Hoyer M; Iyengar P; Kindts I; Méndez Romero A; Nevens D; Palma D; Park C; Ricardi U; Scorsetti M; Yu J; Woodward WA
Radiother Oncol; 2020 Jul; 148():157-166. PubMed ID: 32388150
[TBL] [Abstract][Full Text] [Related]
20. A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management.
Robin TP; Raben D; Schefter TE
Semin Radiat Oncol; 2018 Oct; 28(4):288-294. PubMed ID: 30309639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
